drugset / Trial / NCT02699385

A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis

NCT02699385

Phase 3 Terminated 10 enrolled Janssen-Cilag International NV
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate that domperidone suspension plus oral rehydration therapy (ORT) is more effective than placebo plus ORT at reducing the symptoms of vomiting associated with acute gastroenteritis (AG) within the first 48 hours of treatment administration in pediatric participants with AG and mild-to-moderate dehydration.

Timeline

Start
2015-12-07
Primary completion
2017-08-03
Completion
2017-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Domperidone Unknown 0.25 mg/kg Oral

Indications